Filter by:
The French Monitoring Centre for Drugs and Drug Addiction (OFDT) publishes the first results of the Study on the use of analgesic opioid medicines (entitled EMOA).
In the general context of a background of booming global cocaine production, this Théma report provides an assessment of the situation in France.
The aim of this report is to present updated data on opioid substitution treatment in France. It is based on the latest available data, the year of which may vary from 2019 to 2022 depending on the source and the treatment period.
In March 2022, the ESCAPAD survey interviewed a representative sample of 23 701 French girls and boys with an average age of 17.4 years.
This report of the RECAP survey (common data collection on addictions and treatments) reviews the main recent changes in the statistics on people with addictive behaviour problems accompanied and cared for by teams from specialised drug treatment centres (CSAPA in French).
What is 3-MMC? What do the analyses of the SINTES network reveal? What are the uses observed by TREND?
After 2020, a year marked by the health crisis - which severely restricted the supply of games - and 2021, a year marked by a “catch-up” effect, 2022 stands out for its high levels, with a strong recovery in casino activity and economic growth benefiting all gaming segments.
In 2021, the quantities seized by the police, the gendarmerie and customs have reached unprecedented levels for marijuana, cocaine and even heroin. In addition, the levels of substances circulating the country from cannabis resin and heroin to cocaine and MDMA/ecstasy are high, while retail prices are fairly stable or down slightly.
This issue of Tendances No. 154 looks back on the development of freebase cocaine use among the most vulnerable drug users and their difficulties in accessing care during 2021, a year marked by the measures taken in response to the Covid-19 pandemic.
In 2021, the Health Barometer survey conducted by Santé publique France questioned 23 661 adults about their cannabis use.